Showing results (211-220 of 550) with videos related to

Sort By:
Pageof 55
Molecular Ecology Resources|May 19, 2011
PERMANENT GENETIC RESOURCES: Polymorphic microsatellite loci and interspecific cross-amplification in the parasitoid wasps Megastigmus stigmatizans and Megastigmus dorsalisS Garnier, M Verduijn, S Preuss, et al.
Brachytherapy|November 3, 2009
Do high radiation doses in locally advanced prostate cancer patients treated with 103Pd implant plus external beam irradiation cause increased urinary, rectal, and sexual morbidity?Nelson N Stone, Jamie A Cesaretti, Barry Rosenstein, et al.
Urological Research|January 1, 1987
Aromatization of androstenedione to estrogen by benign prostatic hyperplasia, prostate cancer and expressed prostatic secretionsN N Stone, V P Laudone, W R Fair, et al.
Urology|February 5, 2013
Long-term outcomes and toxicity in patients treated with brachytherapy for prostate adenocarcinoma younger than 60 years of age at treatment with minimum 10 years of follow-upMichael Buckstein, Todd J Carpenter, Nelson N Stone, et al.
BJU International|June 19, 2013
The relative importance of hormonal therapy and biological effective dose in optimizing prostate brachytherapy treatment outcomesRichard G Stock, Michael Buckstein, Jerry T Liu, et al.
Technology in Cancer Research & Treatment|August 2, 2003
Raman spectral mapping in the assessment of axillary lymph nodes in breast cancerJ Smith, C Kendall, A Sammon, et al.
Biochemical Pharmacology|December 15, 1982
Impairment of absorption of ascorbic acid following ingestion of aspirin in guinea pigsC Ioannides, A N Stone, P J Breacker, et al.
Current Urology Reports|March 15, 2011
Update on prostate brachytherapy: long-term outcomes and treatment-related morbidityJohnny Kao, Jamie A Cesaretti, Nelson N Stone, et al.
Urologic Oncology|December 12, 2002
Association between American Urologic Association (AUA) urinary symptom score and disease stage in men with localized prostate cancerSteven Lehrer, Nelson N Stone, Michael J Droller, et al.
Brachytherapy|April 6, 2004
What is the optimal dose for 125I prostate implants? A dose-response analysis of biochemical control, posttreatment prostate biopsies, and long-term urinary symptomsRichard G Stock, Nelson N Stone, Mehud Dahlal, et al.
Pageof 55